Used in cancer immunotherapy to induce apoptosis in tumor cells by activating the TRAIL receptor pathway. Binds specifically to TRAILR1 (DR4), triggering programmed cell death in malignant cells while sparing normal cells. Investigated in clinical trials for solid tumors and hematological malignancies, often in combination with chemotherapy or other targeted agents. Shows potential for overcoming resistance to conventional therapies in certain cancers.